Actinium Pharmaceuticals Inc (NYSE AMERICAN:ATNM), a US-based developer of targeted radiotherapies, announced on Monday that it has signed an agreement with German isotope technology specialist Eckert & Ziegler for the supply of Actinium-225 (Ac-225).

Under the agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's Actinium-225 to further develop its lead product, Actimab-A, and additional early and late-stage development candidates for US and international clinical trials.

Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukaemia (AML) and other myeloid indications.

Sandesh Seth, Actium Pharmaceuticals chairman and CEO, said: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating patients with myeloid malignancies and solid tumours. As we have highlighted recently, we are advancing our lead targeted radiotherapy Actimab-A into a pivotal Phase 2/3 trial for patients with relapsed or refractory acute myeloid leukaemia and in the frontline setting in a Phase 1 trial under our CRADA with the NCI. Additionally, we have launched our Actimab-A solid tumour programme to combine with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials.

"As a pioneer in the development of target radiotherapies, we have aggressive plans to expand our clinical pipeline to address indications with high unmet needs. With this supply agreement with Eckert & Ziegler, we will have access to reliable and constant supply of Ac-225 to advance our product development both in the U.S. as well as internationally."